J&J Posts Second-Quarter Results, Holds the Line with Guidance

publication date: Jul 23, 2011
author/source: Valuentum Analysts
Previous | Next

In our latest article on Johnson & Johnson (JNJ), we indicated we’d like to see continued growth in international sales as well as some recovery in the OTC/nutritionals business (Tylenol, Motrin) in the U.S. Let’s see how J&J measured up in its second quarter.

The firm’s results were in line with our estimates, and the firm kept its full-year earnings guidance at $4.90-$5.00 per share.  Net earnings, excluding special items, were $3.5 billion, or $1.28 a share (the street was expecting $1.24 per share), which excludes one-time expenses related to restructuring Cordis, a company that makes drug-coated stents, and litigation surrounding the DePuy hip recalls. This reflects bottom-line growth of about 5% from the same period a year ago.

Sales in all three segments were up over the same quarter last year, led by pharmaceutical sales (over a 12% increase) which had strong international growth of 22.6%, including a positive currency impact of nearly 12%. As anticipated, Levaquin (a treatment for bacterial infections), which lost patent protection during the quarter, showed a decrease in sales of nearly 50%, but J&J’s pipeline filled the gap with strong performers, including Remicade (a treatment for immune mediated inflammatory diseases) and Stelara (a treatment for plaque psoriasis). We’re also quite bullish on J&J’s drug pipeline. During the quarter, the FDA approved Zytiga (a treatment for prostate cancer), Edurant (an HIV-1 drug), and Xarelto (an anticoagulant). 

The firm’s Medical Devices & Diagnostics segment (7.2% increase in sales) had essentially flat sales in the U.S., but got a boost from international sales (up 13.4%) that was mainly due to a currency impact of 11.2%. J&J showed strength in Ethicon’s surgical care and sterilization products, but experienced some weakness from competitive pressures in drug-eluting stents.

The Consumer Products segment still struggled in the US due to previously announced recalls and the temporary closure of its Pennsylvania manufacturing facility, delivering an 8.5% decrease in U.S. sales that was offset by a 12.4% increase in international sales. The problems in OTC/Nutritionals will continue to plague the company for the next few quarters as the company does not expect the impacted products to return to the shelves until mid-2012 and in the meantime consumers are turning to private label products to fill their needs.

We believe J&J will continue to rely on international sales to boost flatter domestic performance, relying on the strength in pharmaceuticals and medical devices to weather the storm in OTC/Nutritionals through the next year. We don’t expect the firm’s Consumer Products group to recover until early to mid- 2012, but if the hiccups continue there may be an opportunity to pick up shares below our $60 threshold.

The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Valuentum Exclusive publication, ESG Newsletter, and any reports, data and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, data or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor, and does not offer brokerage or investment banking services. The sources of the data used on this website and reports are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum, its employees, and independent contractors may have long, short or derivative positions in the securities mentioned on this website. The High Yield Dividend Newsletter portfolio, ESG Newsletter portfolio, Best Ideas Newsletter portfolio and Dividend Growth Newsletter portfolio are not real money portfolios. Performance, including that in the Valuentum Exclusive publication and additional options commentary feature, is hypothetical and does not represent actual trading. Actual results may differ from simulated information, results, or performance being presented. For more information about Valuentum and the products and services it offers, please contact us at info@valuentum.com.

Previous | Next